Hot Investor Mandate: Global Pharma CVC Invests in Seed and Series A Therapeutics, Drug Discovery, and Enabling Technologies

The firm is the corporate venture capital arm of a global pharmaceutical company, operating through an evergreen investment structure with approximately €350M in capital. The firm focuses on early-stage biotechnology companies developing first-in-class, disease-modifying therapeutics and enabling technologies. The firm primarily invests at the Seed and Series A stages, frequently serving as a lead or co-lead investor alongside institutional syndicate partners. The firm also supports company formation and takes a long-term investment approach, structuring investments as equity financings without requiring commercial rights, licensing options, or acquisition rights. The firm invests globally, with activity across North America, Europe, and Asia.

The firm focuses on innovative therapeutics and enabling technologies across oncology, regenerative medicine, autoimmune diseases, infectious diseases, and digital technologies supporting pharmaceutical research and development. Areas of particular interest include immuno-oncology, targeted therapies, cell reprogramming, tissue regeneration, neurodegenerative diseases, and antimicrobial resistance. The firm also evaluates technologies that improve drug discovery, translational research, and clinical development. The firm primarily targets preclinical-stage assets and differentiated technology platforms capable of supporting multiple therapeutic programs, while remaining open to emerging approaches with significant potential to transform healthcare.

From a company and management team perspective, the firm invests in privately held biotechnology companies with proprietary technologies, strong scientific differentiation, and substantial long-term therapeutic potential. The firm generally favors technology platforms capable of generating multiple development programs rather than single-asset businesses. The firm frequently participates as an early institutional investor, seeks meaningful minority ownership positions, and typically requires a voting board seat. The firm actively supports portfolio companies through corporate strategy, scientific development, leadership recruitment, financing, and long-term company building.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: US-Based VC Firm Invests $250K–$3M in Seed and Series A HealthTech, MedTech, and Biotechnology Companies

The firm is a U.S.-based venture capital investor managing multiple investment vehicles with complementary investment strategies. Through its healthcare-focused fund, the firm primarily invests in Seed and Series A companies, making initial equity investments ranging from $250K–$3M. The firm prefers to lead financing rounds and requires board representation, although co-investments may also be considered. Through a separate diversified investment vehicle, the firm makes smaller investments of approximately $100K–$250K across a broader range of industries and development stages, including later-stage and Pre-IPO opportunities. The firm primarily invests in the United States and may consider international companies that have completed applicable regulatory processes.

The firm’s healthcare investment strategy focuses on healthtech, medical technology, and biotechnology, with particular interest in in vitro diagnostics, software-based digital health solutions, gene editing, and cell therapies. Within medical devices and diagnostics, the firm considers Class I and 510(k) regulatory pathways but generally excludes devices requiring Premarket Approval (PMA). The firm prioritizes revenue-generating companies demonstrating commercial scalability, repeat customers, and recurring business opportunities. The firm’s diversified investment strategy also considers companies across artificial intelligence, technology, aerospace, defense, and other high-growth industries.

From a company and management team perspective, the firm takes a founder-friendly approach and does not impose strict management team requirements. For healthcare investments, the firm emphasizes commercial traction, scalable business models, and demonstrated customer demand. The firm generally prefers to lead healthcare financing rounds and requires a board seat to maintain active governance involvement. Investment requirements and governance expectations under the firm’s diversified investment strategy may vary depending on the opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Global Therapeutics VC Invests Up to $5-6M in Seed to Series B Genetic Medicine and Advanced Therapeutic Modalities

The firm is a Europe-based venture capital investor focused exclusively on therapeutics, with an investment team spanning Europe, North America, and the Middle East. The firm typically makes several new investments annually and invests from Seed through Series B, with commitments of up to approximately $5M–$6M per company. The firm is flexible regarding financing structures and considers traditional equity investments, SAFEs, and convertible notes. The firm can co-lead financing rounds or participate in investment syndicates. The firm invests globally, with significant investment activity in North America.

The firm invests exclusively in therapeutics and has a particular preference for advanced therapeutic modalities, especially genetic medicines. The firm is broadly indication-agnostic and considers a wide range of therapeutic approaches on a case-by-case basis. The firm focuses on preclinical-stage companies developing differentiated therapeutic technologies with strong scientific foundations and the potential to address meaningful unmet medical needs. While advanced modalities represent a priority, the firm remains open to other therapeutic technologies demonstrating compelling scientific and commercial potential.

From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition or prior entrepreneurial experience. The firm seeks companies developing differentiated therapeutic programs with credible scientific rationale and opportunities for significant value creation. The firm is comfortable participating alongside other investors and may take a co-lead role depending on the financing opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Healthcare-Focused Impact VC Targets Series A Oncology Therapeutics and Cardiovascular Medical Devices

The firm is an impact-oriented venture capital investor focused on advancing innovative healthcare technologies with significant clinical and commercial potential. The firm is developing a dedicated healthcare investment fund targeting approximately $150M in commitments and primarily invests at the Series A stage. The firm deploys equity capital to support companies approaching important clinical, regulatory, or commercial milestones. The firm primarily targets opportunities in the United States, with selective interest in Europe and Israel.

The firm focuses on oncology therapeutics, cardiovascular medical devices, and other differentiated healthcare innovations. Within oncology, the firm is modality-agnostic and evaluates novel therapeutic approaches with strong scientific rationale and clearly defined development pathways. The firm generally prefers therapeutic programs approaching IND clearance or entering early clinical development. Within medical devices, the firm has a particular interest in cardiovascular technologies and prioritizes FDA-regulated products requiring Premarket Approval (PMA), while remaining open to select 510(k) devices. Medical device companies are generally expected to have a functional prototype. The firm may also consider opportunities outside its core sectors when technologies demonstrate exceptional innovation and substantial growth potential.

From a company and management team perspective, the firm seeks experienced leadership teams capable of executing clinical development, regulatory, and commercialization strategies. The firm prioritizes strong scientific foundations, credible development plans, and clear pathways toward meaningful patient impact. The firm takes an engaged investment approach and supports portfolio companies through strategic guidance, governance participation, and access to clinical, regulatory, and industry networks.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Global Life Sciences CVC Invests in Series A and B Therapeutics, Diagnostics, and Drug Discovery Technologies

The firm is the corporate venture capital arm of a diversified global company with established businesses across healthcare, advanced materials, and imaging technologies. The firm manages a dedicated life sciences investment fund focused on innovative technologies with strong commercial and strategic potential. Initial investments typically begin in the several-hundred-thousand-dollar range, with capacity for follow-on investments. The firm primarily targets Series A and Series B companies and generally participates as a co-investor. The firm invests globally, with opportunities evaluated based on their alignment with the parent company’s healthcare and life sciences businesses.

The firm invests across therapeutics, diagnostics, medical technologies, and drug discovery enabling technologies. Areas of particular interest include regenerative medicine, cell therapies, small molecules, and innovative R&D platforms. Within diagnostics and medical technology, the firm evaluates medical imaging systems, endoscopy, ultrasound, in vitro diagnostics, veterinary diagnostics, and AI-enabled diagnostic technologies. The firm is broadly opportunistic across therapeutic indications and prioritizes technologies that complement its existing capabilities in healthcare, biotechnology, and life sciences. The firm is comfortable evaluating early-stage technologies, including preclinical therapeutic programs and products still under development.

From a company and management team perspective, the firm does not impose specific requirements regarding team composition or organizational maturity. The firm seeks differentiated technologies with strong growth potential and opportunities for strategic collaboration. Beyond equity investments, the firm may explore research collaborations, licensing, and other strategic partnerships that leverage its parent company’s research, manufacturing, and commercialization capabilities.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: US-Based Fund Invests $1–3M in Seed and Series A Life Sciences, Digital Health, and Healthcare Services Companies in Women’s Health

The firm is a U.S.-based venture capital investor focused exclusively on women’s health, with investments spanning life sciences, digital health, and technology-enabled healthcare services. The firm primarily invests at the Seed and Series A stages, typically committing $1M–$3M per investment. The firm can lead or co-lead financing rounds and takes an active approach to portfolio development, often seeking board representation or observer rights. The firm primarily targets U.S.-based companies but also considers international opportunities when investment proceeds support U.S.-focused activities, including regulatory development, clinical validation, or commercialization.

The firm invests in healthcare solutions addressing conditions that exclusively or disproportionately affect women, as well as diseases where female-specific physiology creates opportunities to improve diagnosis, treatment, and clinical outcomes. The firm evaluates opportunities across therapeutics, medical devices, diagnostics, digital health, and technology-enabled healthcare delivery. Investment decisions are guided by four principal considerations: transformative innovation, access to care, affordability, and systemic improvement in healthcare delivery. The firm prioritizes technologies and business models capable of improving patient outcomes, reducing barriers to adoption, and addressing significant gaps in women’s healthcare.

From a company and management team perspective, the firm seeks differentiated healthcare solutions with strong commercial potential and a clear pathway to the U.S. market. The firm places particular emphasis on measurable patient impact, scalability, and the ability to improve healthcare accessibility and affordability. The firm takes an active role in supporting portfolio companies through strategic guidance, governance participation, business development, and commercialization planning.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: US-Based Early-Stage Life Sciences Investment Firm Backs Pre-Seed to Series A Therapeutics, MedTech, and Biotechnology Platforms

The firm is a U.S.-based life sciences venture development and investment organization focused on supporting early-stage biotechnology and medical technology companies. The firm invests from Pre-Seed through Series A and combines financial investment with laboratory infrastructure, specialized equipment, operational resources, and company-building support. The firm utilizes multiple investment structures, including direct early-stage equity investments and in-kind arrangements that provide access to laboratory facilities and other resources in exchange for equity. The firm primarily operates within major U.S. life sciences innovation ecosystems.

The firm invests exclusively in life sciences, including therapeutics, medical devices, diagnostics, biotechnology platforms, and enabling healthcare technologies. Areas of interest include drug discovery, precision medicine, oncology, cell and gene therapies, advanced diagnostics, medical technologies, and life science tools. The firm prioritizes differentiated scientific innovations with strong translational potential and meaningful clinical applications. The firm is particularly interested in very early-stage technologies emerging from academic institutions, research centers, and healthcare systems that can benefit from dedicated infrastructure and company development support.

From a company and management team perspective, the firm seeks founders and technical teams developing scientifically differentiated technologies with strong commercial potential. The firm places significant emphasis on scientific validation, technical expertise, and the ability to address substantial unmet medical needs. The firm provides hands-on support in company formation, fundraising, operational strategy, talent recruitment, and commercialization planning. The firm also facilitates access to scientific advisors, industry partners, institutional investors, and specialized research infrastructure to accelerate portfolio company development.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.